中国新药杂志

高脂血症不良反应在多靶点抗肿瘤药物疗效预测中的作用研究进展

PDF下载

徐姗 , 朱仲玲 , 阎昭

中国新药杂志 | 综述 2021,30(23): 2173-2177

收起

中国新药杂志 |综述 2021 , 30 (23) : 2173 -2177

高脂血症不良反应在多靶点抗肿瘤药物疗效预测中的作用研究进展

全屏

[Author(id=1322127341413843026, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=postgraduate_xs@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322127341514506324, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, authorId=1322127341413843026, language=EN, stringName=Shan XU, firstName=Shan, middleName=null, lastName=XU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127341929742421, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, authorId=1322127341413843026, language=CN, stringName=徐姗, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060, bio={"content":"

徐姗，女，药师，主要从事治疗药物的监测工作。E-mail：postgraduate_xs@163.com。

"}, bioImg=null, bioContent=

徐姗，女，药师，主要从事治疗药物的监测工作。E-mail：postgraduate_xs@163.com。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127341057327182, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, xref=null, ext=[AuthorCompanyExt(id=1322127341069910095, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, companyId=1322127341057327182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China), AuthorCompanyExt(id=1322127341078298704, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, companyId=1322127341057327182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060)])]), Author(id=1322127342189789272, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322127342344978522, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, authorId=1322127342189789272, language=EN, stringName=Zhong-ling ZHU, firstName=Zhong-ling, middleName=null, lastName=ZHU, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127342416281691, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, authorId=1322127342189789272, language=CN, stringName=朱仲玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127341057327182, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, xref=null, ext=[AuthorCompanyExt(id=1322127341069910095, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, companyId=1322127341057327182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China), AuthorCompanyExt(id=1322127341078298704, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, companyId=1322127341057327182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060)])]), Author(id=1322127342617608285, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=yanzhaopaper@163.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322127342709882975, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, authorId=1322127342617608285, language=EN, stringName=Zhao YAN, firstName=Zhao, middleName=null, lastName=YAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322127343041232992, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, authorId=1322127342617608285, language=CN, stringName=阎昭, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322127341057327182, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, xref=null, ext=[AuthorCompanyExt(id=1322127341069910095, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, companyId=1322127341057327182, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China), AuthorCompanyExt(id=1322127341078298704, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322127338435887175, companyId=1322127341057327182, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060)])])]

徐姗, 朱仲玲, 阎昭

作者信息

天津医科大学肿瘤医院临床药理研究室，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心，天津　300060

通讯作者:

阎昭，男，主任药师，主要从事抗肿瘤新药临床评价。联系电话：(022)23340123-6416，E-mail：yanzhaopaper@163.com。

作者简介:

徐姗，女，药师，主要从事治疗药物的监测工作。E-mail：postgraduate_xs@163.com。

Research progress on the role of hyperlipidemia in efficacy prediction of multitargeted antitumor drugs

Shan XU, Zhong-ling ZHU, Zhao YAN

Affiliations

Department of Clinical Pharmacology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin 300060, China

出版时间: 2021-12-15

文章导航

摘要

收起

多靶点抗肿瘤药物在肿瘤治疗领域已取得显著疗效，高脂血症作为常见的不良反应正在被广泛关注。本文选取5种临床应用较多的同类药物，重点关注其高脂血症的发病现状，并对可能诱发高脂血症的机制进行探讨，旨在探索高脂血症与该类药物疗效之间的关联，为进一步阐明相关机制奠定基础，从而有助于筛选合适的目标治疗患者，制订合理的治疗方案，提高患者的生存获益。

关键词

高脂血症 / 多靶点 / 抗肿瘤药物 / 疗效预测标志物

Abstract

收起

Multitargeted tyrosine kinase inhibitors have shown significant therapeutic effects in antitumor therapy. As one of the most common side effects, hyperlipidemia has drawn increasing attentions. Five similar drugs were selected in this review in order to investigate the relationship between hyperlipidemia and therapeutic outcomes of multitargeted tyrosine kinase inhibitors and further illustrate the underlying mechanisms. The reported occurrences of hyperlipidemia in patients treated with them were summarized and possible mechanisms of treatment-induced hyperlipidemia were discussed, which would benefit for searching optimal targeted patients and designing rational therapeutic schedules to improve the survival benefits of patients with carcinomas.

Key words

hyperlipidemia / multitarget / antitumor drugs / predictive markers

引用本文

徐姗, 朱仲玲, 阎昭. 高脂血症不良反应在多靶点抗肿瘤药物疗效预测中的作用研究进展. 中国新药杂志, 2021 , 30 (23) : 2173 -2177 .

Shan XU, Zhong-ling ZHU, Zhao YAN. Research progress on the role of hyperlipidemia in efficacy prediction of multitargeted antitumor drugs[J]. Chinese Journal of New Drugs, 2021 , 30 (23) : 2173 -2177 .

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

[1]

LAI Y, ZHAO Z, ZENG T, et al. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma[J]. Cancer Cell Int, 2018, 18(1): 31-39.

[2]

CROSS MJ, CLAESSON-WELSH L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition[J]. Trends Pharmacol Sci, 2001, 22(4): 201-207.

[3]

ELLIS PM. Anti-angiogenesis in personalized therapy of lung cancer[J]. Adv Exp Med Biol, 2016, 893: 91-126.

[4]

YUMURA M, NAGANO T, NISHIMURA Y. Novel multitarget therapies for lung cancer and respiratory disease[J]. Molecules, 2020, 25(17): 3987-4002.

[5]

ZHU XD, TANG ZY, SUN HC. Targeting angiogenesis for liver cancer: Past, present, and future[J]. Genes Dis, 2020, 7(3): 328-335.

[6]

BROSE MS, BIBLE KC, CHOW L, et al. Management of treatment-related toxicities in advanced medullary thyroid cancer[J]. Cancer Treat Rev, 2018, 66: 64-73.

[7]

KIM HS, HONG MH, KIM K, et al. Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles[J]. Oncology, 2011, 80(5-6): 395-405.

[8]

HUTTERER M, NOWOSIELSKI M, HAYBAECK J, et al. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07)[J]. Neuro Oncol, 2014, 16(1): 92-102.

[9]

ARMSTRONG AJ, HALABI S, EISEN T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial[J]. Lancet Oncol, 2016, 17(3): 378-388.

[10]

BALAÑA C, GIL MJ, PEREZ P, et al. Sunitinib administered prior to radiotherapy in patients with non-resectable glioblastoma: results of a phase II study[J]. Target Oncol, 2014, 9(4): 321-329.

[11]

HUTSON TE, ESCUDIER B, ESTEBAN E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma[J]. J Clin Oncol, 2014, 32(8): 760-767.

[12]

FLAHERTY KT, MANOLA JB, PINS M, et al. BEST: a randomized phase II study of vascular endothelial growth factor, RAF kinase, and mammalian target of rapamycin combination targeted therapy with bevacizumab, sorafenib, and temsirolimus in advanced renal cell carcinoma: a trial of the ECOG-ACRIN cancer research group (E2804)[J]. J Clin Oncol, 2015, 33(21): 2384-2391.

[13]

JUNG KS, LEE SJ, PARK SH, et al. Pazopanib for the treatment of non-clear cell renal cell carcinoma: a single-arm, open-label, multicenter, phase II study[J]. Cancer Res Treat, 2018, 50(2): 488-494.

[14]

KOINIS F, AGELAKI S, KARAVASSILIS V, et al. Second-line pazopanib in patients with relapsed and refractory small-cell lung cancer: a multicentre phase II study of the Hellenic Oncology Research Group[J]. Br J Cancer, 2017, 117(1): 8-14.

[15]

BESSE B, MAZIÉRES J, RIBASSIN-MAJED L, et al. Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial[J]. Ann Oncol, 2017, 28(5): 1078-1083.

[16]

PHAN AT, HALPERIN DM, CHAN JA, et al. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study[J]. Lancet Oncol, 2015, 16(6): 695-703.

[17]

BIBLE KC, SUMAN VJ, MOLINA JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study[J]. Lancet Oncol, 2010, 11(10): 962-972.

[18]

IWAMOTO FM, LAMBORN KR, ROBINS HI, et al. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)[J]. Neuro Oncol, 2010, 12(8): 855-861.

[19]

SHARMA M, SCHILERO C, PEEREBOOM DM, et al. Phase II study of Dovitinib in recurrent glioblastoma[J]. J Neurooncol, 2019, 144(2): 359-368.

[20]

MILOWSKY MI, DITTRICH C, DURÁN I, et al. Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma[J]. Eur J Cancer, 2014, 50(18): 3145-3152.

[21]

KONECNY GE, FINKLER N, GARCIA AA, et al. Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study[J]. Lancet Oncol, 2015, 16(6): 686-694.

[22]

KEAM B, KIM SB, SHIN SH, et al. Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma[J]. Cancer, 2015, 121(15): 2612-2617.

[23]

MOTZER RJ, PORTA C, VOGELZANG NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15(3): 286-296.

[24]

ESCUDIER B, GRÜNWALD V, RAVAUD A, et al. Phase II results of Dovitinib (TKI258) in patients with metastatic renal cell cancer[J]. Clin Cancer Res, 2014, 20(11): 3012-3022.

[25]

SUN Y, DU F, GAO M, et al. Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer[J]. Thyroid, 2018, 28(11): 1455-1461.

[26]

CHI Y, FANG ZW, HONG XN, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma[J]. Clin Cancer Res, 2018, 24(21): 5233-5238.

[27]

ZHOU AP, BAI Y, SONG Y, et al. Anlotinib versus sunitinib as first-line treatment for metastatic renal cell carcinoma: a randomized phase II clinical trial[J]. Oncologist, 2019, 24(8): e702-e708.

[28]

HAN B, LI K, WANG Q, et al. Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: the ALTER 0303 phase 3 randomized clinical trial[J]. JAMA Oncol, 2018, 4(11): 1569-1575.

[29]

HAN B, LI K, ZHAO Y, et al. Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)[J]. Br J Cancer, 2018, 118(5): 654-661.

[30]

YOU M, ARTEEL GE. Effect of ethanol on lipid metabolism[J]. J Hepatol, 2019, 70(2): 237-248.

[31]

NIES VJ, SANCAR G, LIU W, et al. Fibroblast growth factor signaling in metabolic regulation[J]. Front Endocrinol (Lausanne), 2015, 6: 193-207.

[32]

YANG C, JIN C, LI X, et al. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB[J]. PLoS One, 2012, 7(3): e33870.

[33]

SOMM E, JORNAYVAZ FR. Fibroblast growth factor 15/19: from basic functions to therapeutic perspectives[J]. Endocr Rev, 2018, 39(6): 960-989.

[34]

HUANG X, YANG C, LUO Y, et al. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet induced fatty liver[J]. Diabetes, 2007, 56(10): 2501-2510.

[35]

CHENNAMSETTY I, CLAUDEL T, KOSTNER KM, et al. FGF19 signaling cascade suppresses APOA gene expression[J]. Arterioscler Thromb Vasc Biol, 2012, 32(5): 1220-1227.

[36]

BHATNAGAR S, DAMRON HA, HILLGARTNER FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis[J]. J Biol Chem, 2009, 284(15): 10023-10033.

[37]

BOUCHER P, LIU P, GOTTHARDT M, et al. Platelet-derived growth factor mediates tyrosine phosphorylation of the cytoplasmic domain of the low Density lipoprotein receptor-related protein in caveolae[J]. J Biol Chem, 2002, 277(18): 15507-15513.

[38]

FAUBERT B, BOILY G, IZREIG S, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo[J]. Cell Metab, 2013, 17(1): 113-124.

[39]

CARLING D. AMPK signalling in health and disease[J]. Curr Opin Cell Biol, 2017, 45: 31-37.

[40]

ZHANG X, SONG Y, FENG M, et al. Thyroid-stimulating hormone decreases HMG-CoA reductase phosphorylation via AMP-activated protein kinase in the liver[J]. J Lipid Res, 2015, 56(5): 963-971.

[41]

LADEROUTE KR, CALAOAGAN JM, MADRID PB, et al. SU11248 (sunitinib) directly inhibits the activity of mammalian 5'-AMP-activated protein kinase (AMPK)[J]. Cancer Biol Ther, 2010, 10(1): 68-76.

[42]

WU JL, HUANG H. Acquired hypothyroidism in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors[J]. Drug Des Dev Ther, 2020, 14: 3977-3982.

[43]

BUDA-NOWAK A, KUCHARZ J, DUMNICKA P, et al. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients[J]. Med Oncol, 2017, 34(4): 68-71.

[44]

BOZKURT O, KARACA H, HACIBEKIROGLU I, et al. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?[J]. J Chemother, 2016, 28(3): 230-234.

[45]

TASSI R, BALDAZZI V, LAPINI A, et al. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?[J]. Clin Genitourin Cancer, 2015, 13(2): e101-e105.

[46]

SAG D, CEKIC C, WU R, et al. The cholesterol transporter ABCG1 links cholesterol homeostasis and tumour immunity[J]. Nat Commun, 2015, 6(1): 5904-5912.

[47]

YANG W, BAI Y, XIONG Y, et al. Potentiating the antitumour response of CD8(+) T cells by modulating cholesterol metabolism[J]. Nature, 2016, 531(7596): 651-655.

[48]

SONG Y, DU C, ZHANG W, et al. A study on the association between hyperlipidemia and hypothyroidism and the response to TKIs in metastatic renal cell carcinoma[J]. Asia Pac J Clin Oncol, 2016, 12(2): 174-180.

[49]

WANG J, ZHAO Y, WANG Q, et al. Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment[J]. Cancer Biol Med, 2018, 15(4): 443-451.

2021年第30卷第23期

PDF下载

引用本文

BibTeX

文章信息

首发时间：2026-10-28
出版时间：2021-12-15

补充材料

相关文章

文章信息

作者

出版历史

录用日期：2021-04-25

基金

作者信息

通讯作者:

阎昭，男，主任药师，主要从事抗肿瘤新药临床评价。联系电话：(022)23340123-6416，E-mail：yanzhaopaper@163.com。

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322127338435887175

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT